Our laboratory recently developed a mouse model of transplacental induction of
lymphoma, lung and
liver cancer by the
polycyclic aromatic hydrocarbon,
dibenzo[a,l]pyrene (DBP). Pregnant B6129SF1 females, bred to 129S1/SvIm males, were treated on day 17 of gestation with an oral dose of 15 mg/kg DBP. Beginning on day 0 of gestation, dams were given (ad lib) buffered water, 0.5%
green tea, 0.5% decaffeinated
green tea,
caffeine or
epigallocatechin-3-gallate (EGCG) (both at equivalent concentrations found in
tea). The concentration of the teas (and corresponding
caffeine and EGCG) was increased to 1.0% upon entering the second trimester, 1.5% at onset of the third trimester and continued at 1.5% until pups were weaned at 21 days of age. Offspring were raised with normal
drinking water and AIN93G diet. Beginning at 2 months of age, offspring experienced significant mortalities due to an aggressive
T-cell lymphoma as seen in our previous studies. Ingestion of caffeinated, but not decaffeinated,
green tea provided modest but significant protection (P = 0.03) against mortality.
Caffeine provided a more robust (P = 0.006) protection, but EGCG was without effect. Offspring also developed DBP-dependent lung
adenomas. All treatments significantly reduced lung
tumor multiplicity relative to controls (P < 0.02). EGCG was most effective at decreasing
tumor burden (P = 0.005) by on average over 40% compared with controls. Induction of
Cytochrome P450 (Cyp)1b1 in maternal liver may reduce bioavailability of DBP to the fetus as a mechanism of
chemoprevention. This is the first demonstration that maternal ingestion of
green tea, during pregnancy and nursing, provides protection against transplacental
carcinogenesis.